Daré Bioscience's DARE-HRT1 Shows Potential As Monthly Therapy For Vasomotor, Vaginal Symptoms of Menopause

Daré Bioscience Inc DARE has announced positive topline results from its Phase 1 trial of DARE-HRT1 as part of a hormone therapy (HT) regimen to treat the vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause.
DARE-HRT1 is a novel IVR designed to deliver bio-identical 17β-estradiol and bio-identical progesterone.
Data from the study demonstrated that the levels of estradiol released from both the lower and higher dose formulation of DARE-HRT1 achieved or exceeded the targeted levels for hormone therapy.
The progesterone levels released from both versions of DARE-HRT1 evaluated in the study met the objectives of releasing progesterone.
The treatment was well tolerated, with the most common adverse events consistent with other vaginal products.
There was only one early discontinuation due to an adverse event unrelated to study treatment or participation, and no serious adverse events were reported.
Daré plans to submit data from the Phase 1 clinical study of DARE-HRT1 for publication in a peer-reviewed publication.
Price Action: DARE shares are up 2.96% at $1.74 during the premarket session on the last check Monday.